abdominal painIncreased riskOR=3.21
In Group S, the chance of developing symptoms of ... abdominal pain (OR=3.21) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluanxietyIncreased riskOR=3.58
In Group S, the chance of developing symptoms of ... anxiety (OR=3.58) was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilludiarrheaIncreased riskOR=3.01
In Group S, the chance of developing symptoms of ... diarrhea (OR=3.01) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluheadacheIncreased riskOR=10.51
In Group S, the chance of developing symptoms of ... headache (OR=10.51) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacillunauseaIncreased riskOR=2.74
In Group S, the chance of developing symptoms of nausea (OR=2.74) ... was significantly lower than in the control group (p<0.05).
from: Investigating the effect of quadruple therapy with Saccharomyces boulardii or LactobacilluOverall tolerabilityNo significant difference
The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distensionNo significant differenceRR=0.49, 95% CI: 0.33-0.72
abdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal painNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication constipationNo significant differenceRR=0.38, 95% CI: 0.26-0.57
constipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant differenceRR=0.36, 95% CI: 0.26-0.48
reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication liver and kidney functionNo significant difference
Liver and kidney functions in both groups before and after the therapy did not change significantly.
from: Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual theranauseaNo significant differenceRR=0.50, 95% CI: 0.37-0.68
nausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disordersNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication vomitingNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication Overall tolerabilityReported
this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.
from: Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradicatiOverall tolerabilityReported5.3% vs 21.3%, P=0.004
The incidence of adverse events was significantly lower in the VAS group (5.3%) than in the VA group (21.3%; P = 0.004)
from: Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual theraabdominal painReportedP=0.020
particularly with regard to abdominal pain (P = 0.020)
from: Effects of supplementing with Saccharomyces boulardii on vonoprazan-amoxicillin dual theraadverse reactionsReported
Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment.
from: Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradicatiflatulence/diarrheaReported22% in SB
Adverse effects were epigastric burning and constipation in M (53%) and M+SB (36%), and flatulence/diarrhea in SB (22%).
from: Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial gastrointestinal side effectsReported
the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy and smaller gastrointestinal side effects in eradicating initial H. pylori infections among non-ulcer dyspepsia patients.
from: Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradicati